Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

Prognostic impact of diffuse large B-cell lymphoma subgroups in patients undergoing autologous SCT

Bone Marrow Transplantation volume 43, pages 323–325 (2009)Cite this article

Abstract

A total of 53 patients aged 18–60 years with high-intermediate or high-risk diffuse large B-cell lymphoma (DLBCL) were evaluated to analyze the impact of the cell of origin. Of 53 patients, 16 underwent autologous SCT (ASCT) in first remission and the rest received conventional chemotherapy. Immunohistochemistry was evaluated in 47 cases 17 were of germinal center (GC) origin and 30 were of non-GC origin. There was no survival difference between the two groups. Overall survival (OS) and disease-free survival (DFS) at 3 years were 93 and 83%, respectively, for the 14 patients who underwent ASCT. Their DFS was significantly better than that of patients who achieved CR but did not undergo ASCT. We conclude that ASCT is safe and improves the DFS of high-intermediate and high-risk DLBCL, regardless of the cell of origin. This observation should be confirmed in a larger study.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. The International non-Hodgkin's lymphoma prognostic factors project. A predictive model for aggressive non-Hodgkin lymphoma. N Engl J Med 1993; 329: 987–994.

    Article  Google Scholar 

  2. Sehn LH, Berry B, Chhanabbai M, Fritzgerald C, Gill K, Hoskins P et al. The Revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857–1861.

    Article  CAS  PubMed  Google Scholar 

  3. Chang CC, McClintock S, Cleveland RP, Trzpue T, Vesole DH, Logan B et al. immunohistochemical expression patters of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004; 28: 464–470.

    Article  PubMed  Google Scholar 

  4. Barrans SL, Carter I, Owen RG, Davies FE, Russell DP, Haynes AP et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99: 1136–1143.

    Article  CAS  PubMed  Google Scholar 

  5. Lossos IS, Morgensztern D . Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 995–1007.

    Article  CAS  PubMed  Google Scholar 

  6. Shipp MA, Abeloff MD, Antman KH, Carrol G, Hagenbeek A, Loeffler M et al. International Consensus Conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the Jury. J Clin Oncol 1999; 17: 423–429.

    Article  CAS  PubMed  Google Scholar 

  7. Greb A, Bohlius J, Trelle S, Schiefer D, De Souza CA, Gisselbrecht C et al. High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma—results of a comprehensive meta-analysis. Cancer Treat Rev 2007; 33: 338–346.

    Article  CAS  PubMed  Google Scholar 

  8. Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol—a Group d'Etude des Lymphomes de l'Adulte study. J Clin Oncol 2000; 18: 3025–3030.

    Article  CAS  PubMed  Google Scholar 

  9. Van Imhoff GW, Holt BVD, Mackenzie MA, Veer MBV, Wijermans PW, Ossenkoppele GJ et al. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-Hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40. J Clin Oncol 2005; 23: 3793–3801.

    Article  CAS  PubMed  Google Scholar 

  10. Van Imhoff GW, Boerman EG, Holt BVD, Schuuring E, Verdonck LF, Kluin-Nelemans HC et al. Prognostic impact of germinal center associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 4135–4142.

    Article  CAS  PubMed  Google Scholar 

  11. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282.

    Article  CAS  PubMed  Google Scholar 

  12. Hsu SM, Raine L, Fanger H . Use of avidin–biotin–peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 577–580.

    Article  CAS  PubMed  Google Scholar 

  13. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579–586.

    Article  PubMed  Google Scholar 

  14. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Group d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117–4126.

    Article  CAS  PubMed  Google Scholar 

  15. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by Mabthera International Trial (MinT) Group. Lancet Oncol 2006; 7: 379–391.

    Article  CAS  PubMed  Google Scholar 

  16. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006.

    Article  CAS  PubMed  Google Scholar 

  17. Hallack Neto AE, Pereira J, Dorlhiac-Llacer P, Beitler B, Chamone DAF, Dulley FL et al. A results of CHOP chemotherapy for diffuse large B-cell lymphoma. Braz J Med Biol Res 2006; 39: 1315–1322.

    Article  CAS  PubMed  Google Scholar 

  18. Gisselbrecht C, Lepage E, Molina T, Quesnel B, Fillet G, Lederlin P et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002; 20: 2472–2479.

    Article  CAS  PubMed  Google Scholar 

  19. Betticher DC, Martinelli G, Radford JA, Kaufmann M, Dyer JS, Kaiser U et al. Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). Ann Oncol 2006; 17: 1546–1552.

    Article  CAS  PubMed  Google Scholar 

  20. Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350: 1287–1295.

    Article  CAS  PubMed  Google Scholar 

  21. Kalaycio M, Rybicki L, Pohlman B, Sobecks R, Andresen S, Kuczkowski E et al. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol 2006; 24: 3604–3610.

    Article  PubMed  Google Scholar 

  22. Armitage JO . How I treat patients with diffuse large B-cell lymphoma. Blood 2007; 110: 29–36.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, School of Medicine, Sao Paulo University, Sao Paulo, Brazil

    A E Hallack Neto, F L Dulley, L F Pracchia, M Belesso, R Saboya, D Sturaro, J U Amigo-Filho, A Mendrone Junior, D A F Chamone & J Pereira

  2. Department of Hematology, School of Medicine, Juiz de Fora Federal University, Sao Paulo, Brazil

    A E Hallack Neto

  3. Department of Pathological Anatomy, School of Medicine, Sao Paulo University, Sao Paulo, Brazil

    S A Coelho Siqueira

Authors
  1. A E Hallack Neto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F L Dulley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S A Coelho Siqueira
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L F Pracchia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Belesso
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Saboya
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D Sturaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J U Amigo-Filho
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A Mendrone Junior
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. D A F Chamone
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J Pereira
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A E Hallack Neto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hallack Neto, A., Dulley, F., Coelho Siqueira, S. et al. Prognostic impact of diffuse large B-cell lymphoma subgroups in patients undergoing autologous SCT. Bone Marrow Transplant 43, 323–325 (2009). https://doi.org/10.1038/bmt.2008.330

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.330

Keywords

This article is cited by

Search

Advanced search

Quick links